Earth Science Tech Inc. (ETST) Positioning as Key
Post# of 333
(Total Views: 531)
Posted On: 09/20/2019 5:38:42 PM
Earth Science Tech Inc. (ETST) Positioning as Key Player in Billion-Dollar Industry
- Earth Science Tech offers biotech expertise in the largest sector of the legal cannabis market
- The CBD market is projected to see 700 percent growth through 2019
- ETST’s portfolio is designed to further establish its position in the burgeoning sector
Earth Science Tech Inc. (OTCQB: ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid, nutraceutical, pharmaceutical and medical device research and development. With biotech being the largest sector of the legal cannabis market (http://nnw.fm/U6lZB), ETST appears ideally poised to be a key player in the burgeoning space.
Brightfield Group, a leading market and consumer intelligence firm for the legal cannabinoids and cannabis industries, recently reported that the U.S. CBD market was projected to see an unprecedented 700 percent growth through 2019 (http://nnw.fm/t1Uoq). With hemp-derived CBD increasingly being used in health, wellness and anti-pharma products, the market is actually estimated to reach $23.7 billion by 2023.
Biotech researchers are committed to uncovering innovative new ways that CBD can be used for medicinal and other purposes. ETST recognizes the opportunity and is leveraging its background and expertise in both biotech and cannabis to firmly establish its position in the space. As part of that strategy, the company is widening its reach through strategic partnerships designed to develop new and novel cannabinoid-based pharmaceutical and nutraceutical products.
Included in Earth Science Tech’s portfolio are three wholly owned subsidiaries focused on expanding the company’s work in the pharmaceutical and medical device sectors. These subsidiaries include Cannabis Therapeutics Inc., KannaBidioiD (“KBD”) and Earth Science Pharma.
Cannabis Therapeutics Inc. is leading out in the development of new, cutting-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
KannaBidioiD provides a variety of products designed for the recreational cannabis arena. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and e-liquid products.
Earth Science Pharma Inc. is committed to the development of low-cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
Earth Science Tech’s current and pipeline offerings provide a variety of products and unique formulations. As legalization of medical marijuana spreads, investment opportunities in the cannabis biotech sector continue to grow.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Earth Science Tech offers biotech expertise in the largest sector of the legal cannabis market
- The CBD market is projected to see 700 percent growth through 2019
- ETST’s portfolio is designed to further establish its position in the burgeoning sector
Earth Science Tech Inc. (OTCQB: ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid, nutraceutical, pharmaceutical and medical device research and development. With biotech being the largest sector of the legal cannabis market (http://nnw.fm/U6lZB), ETST appears ideally poised to be a key player in the burgeoning space.
Brightfield Group, a leading market and consumer intelligence firm for the legal cannabinoids and cannabis industries, recently reported that the U.S. CBD market was projected to see an unprecedented 700 percent growth through 2019 (http://nnw.fm/t1Uoq). With hemp-derived CBD increasingly being used in health, wellness and anti-pharma products, the market is actually estimated to reach $23.7 billion by 2023.
Biotech researchers are committed to uncovering innovative new ways that CBD can be used for medicinal and other purposes. ETST recognizes the opportunity and is leveraging its background and expertise in both biotech and cannabis to firmly establish its position in the space. As part of that strategy, the company is widening its reach through strategic partnerships designed to develop new and novel cannabinoid-based pharmaceutical and nutraceutical products.
Included in Earth Science Tech’s portfolio are three wholly owned subsidiaries focused on expanding the company’s work in the pharmaceutical and medical device sectors. These subsidiaries include Cannabis Therapeutics Inc., KannaBidioiD (“KBD”) and Earth Science Pharma.
Cannabis Therapeutics Inc. is leading out in the development of new, cutting-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
KannaBidioiD provides a variety of products designed for the recreational cannabis arena. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and e-liquid products.
Earth Science Pharma Inc. is committed to the development of low-cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
Earth Science Tech’s current and pipeline offerings provide a variety of products and unique formulations. As legalization of medical marijuana spreads, investment opportunities in the cannabis biotech sector continue to grow.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Earth Science Tech, Inc. (ETST) Stock Research Links
Scroll down for more posts ▼